Health Policy Newsletter

Volume 13 Number 3 September, 2000 Article 10

A Business Case for Low Molecular Weight Heparin

Copyright ©2000. *Health Policy Newsletter* is a quarterly publication of TJU, JHS and the Office of Health Policy and Clinical Outcomes, 1015 Walnut Street, Suite 115, Philadelphia, PA 19107.

Suggested Citation:

A business case for low molecular weight heparin. Health Policy Newsletter 2000; 13(3): Article 10. Retrieved [date] from http://jdc.jefferson.edu/hpn/vol13/iss3/10.

A Business Case for Low Molecular Weight Heparin

A Symposium for Medical and Pharmacy Directors, Physicians, Pharmacists, and Case Managers

Continuing Education for Physicians and Pharmacists

Complimentary Registration
Thursday, September 14, 7:30 a.m. to 4:30 p.m.
Hotel Sofitel, Philadelphia, PA

Program Directors: David B. Nash, MD, MBA, Associate Dean, Jefferson Medical College and Director, Office of Health Policy and Clinical Outcomes; Geno J. Merli, MD, Ludwig A. Kind Professor and Director, Division of Internal Medicine and Vice Chairman, Primary Care, Jefferson Medical College.

This one-day program will feature national experts who will present evidence of the economic, clinical and humanistic outcomes regarding the use and implications of low molecular weight heparin (LMWH). Representing different perspectives within the healthcare environment (the managed care organization, the integrated delivery system, the economist, the physician, the pharmacist) the speakers will report on studies and clinical experiences with LMWH and traditional unfractionated heparin.

Jefferson Medical College of Thomas Jefferson University, as a member of the Consortium for Academic Continuing Medical Education, is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

This program is supported by an unrestricted grant from Aventis Pharmaceuticals.

To receive a program brochure please call 215-955-6969.